NEVVI Medicare utilization intelligence
or

← back

Provider profile

SIEGEL, RICHARD MD

Hematology-Oncology · NPI 1730176322 · ARLINGTON HEIGHTS, IL

1
Groups
55
Codes · 2024
63,685
Disclosed services

SIEGEL, RICHARD is a Hematology-Oncology in ARLINGTON HEIGHTS, IL, a member of 1 medical group, who billed 55 distinct codes to Medicare Part B in 2024.

Groups: ILLINOIS CANCER SPECIALISTS (ARLINGTON HEIGHTS, IL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

63,685
disclosed services
55
codes billed to Medicare Part B
Prior year · CY2023 86,940 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9267 Injection, paclitaxel, 1 mg
J0185 Injection, aprepitant, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0897 Injection, denosumab, 1 mg
36415 Insertion of needle into vein for collection of blood sample
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J2469 Injection, palonosetron hcl, 25 mcg
J1626 Injection, granisetron hydrochloride, 100 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9190 Injection, fluorouracil, 500 mg
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
Q5122 Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
96372 Injection of drug or substance under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
J9045 Injection, carboplatin, 50 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
85055 Reticulated (young) platelet measurement
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J3475 Injection, magnesium sulfate, per 500 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
J3490 Unclassified drugs
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J7030 Infusion, normal saline solution , 1000 cc
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
85610 Blood test, clotting time
96360 Infusion into a vein for hydration, 31-60 minutes
96361 Infusion into a vein for hydration, each additional hour
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J0640 Injection, leucovorin calcium, per 50 mg
96415 Administration of chemotherapy into vein, each additional hour
96374 Injection of drug or substance into vein
96411 Administration of additional new drug or substance into vein using push technique
88184 Flow cytometry technique for dna or cell analysis, first marker
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
G0008 Administration of influenza virus vaccine
90653 Influenza vaccine, inactivated
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.